Results 41 to 50 of about 4,608 (197)

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

Myeloid neoplasms after chemotherapy and PRRT: myth and reality [PDF]

Endocrine-Related Cancer, 2016
Peptide receptor radionuclide therapy (PRRT) with 90Y-octreotide or 177Lu-octreotate is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic or bronchopulmonary NETs.
Bodei, Lisa, Modlin, Irvin M, Luster, Markus, Forrer, Flavio, Cremonesi, Marta, Hicks, Rodney J, Ezziddin, Samer, Kidd, Mark, Chiti, Arturo   +8 more
openaire   +3 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

World Journal of Nuclear Medicine, 2022
Background This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs).
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Esmail Jafari, AbdulLatif Amini, Habibollah Dadgar, Mehdi Mahmoudpour, Iraj Nabipour, Narges Jokar, Majid Assadi   +10 more
doaj   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT

Pharmaceutics, 2022
Aim: The most suitable method for assessment of response to peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) is still under debate. In this study we aimed to compare size (RECIST 1.1), density (Choi), Standardized Uptake Value (
Kevin Zwirtz, Juliane Hardt, Güliz Acker, Alexander D. J. Baur, Marianne Pavel, Kai Huang, Winfried Brenner, Vikas Prasad   +7 more
doaj   +1 more source

Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Pancreatic neuroendocrine tumors (PanNETs) are increasingly diagnosed, reflecting greater clinical awareness, improved imaging, and revised classification. This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and
Angelo Bruni, David Meacci, Roberto Falbo, Marco Fichera, Francesco Poggioli, Riccardo Casadei, Claudio Ricci, Leonardo Henry Eusebi   +7 more
wiley   +1 more source

Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center

Indian Journal of Endocrinology and Metabolism
Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT).
David Mathew, Saumya S. Sunny, Justin Benjamin, Junita R. John, Felix K. Jebasingh, Josh T. Georgy, Ashish Singh, Regi Oommen   +7 more
doaj   +1 more source

Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images [PDF]

Journal of Biomedical Physics and Engineering
Background: Radiomics is the computation of quantitative image features extracted from medical imaging modalities to help clinical decision support systems, which could ultimately meliorate personalized management based on individual characteristics ...
Baharak Behmanesh, Akbar Abdi-Saray, Mohammad Reza Deevband, Mahasti Amoui, Hamid Reza Haghighatkhah   +4 more
doaj   +1 more source

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors

Biomedicines, 2022
Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required ...
Johannes Zellmer, Hsi-Yu Yen, Lena Kaiser, Franz Josef Gildehaus, Guido Böning, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug, Harun Ilhan   +10 more
doaj   +1 more source